Research at MD Anderson
Scroll Ahead
Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
FY17 CPRIT Funding Statistics
$19M+
in research grants
$18M
for investigator recruitment
$1.5M
for prevention research
In February, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded MD Anderson with $19.5 million, reflecting the importance and impact of our research. The awards included $18M for the recruitment of established investigators with expertise ranging from molecular mechanisms of cancer and aging to transplanation immunology.
Learn moreDepartments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Jim Allison's Research
Immunotherapy pioneer named among TIME's 100 most influential people
Research Areas
Since 1941, MD Anderson has been home to some of the brightest minds across a variety of cancer research areas.
Resources
MD Anderson provides research tools and resources to fuel the discoveries of our scientists.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program™ was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.
Learn more about the Moon Shots ProgramResearch Highlights
Engineering exosomes
Combination therapies
Breast cancer biomarker
RAS-mutant cancers
Pain research
Metastatic melanoma
Proton therapy trial
Research funding
Conquest
Clinical trials capitalize on cellular therapy
Natural killer (NK) cells have powerful and durable anti-tumor capabilities, but they aren’t robust enough on their own. Our physician-scientists are working to identify and overcome the pathways hindering the cancer-killing potential of these immune cells. So far, our research efforts have resulted in the initiation of five clinical trials that capitalize on the power of NK cells to treat several blood cancers.